The New York Entrepreneur

Merck’s vaccine approval poses threat to one of Pfizer’s top-selling products

Read Time:7 Second

Merck has gained U.S. regulatory approval for a vaccine that could become a tough competitor to one of Pfizer Inc.’s top-selling products.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post French stocks are pressuring widely held equities indexes. Should you buy the dip?
Next post FDA approves Merck vaccine designed to protect adults from bacteria that can cause pneumonia, serious infections